Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV clinical trial of Caelyx + cyclophosphamide + Herceptin in HER2-positive metastatic breast cancer
2005-001117-17Phase 4Active
- Sponsor
- GEICAM
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by GEICAM. Primary endpoint: Objective response rate. Started Nov 2005; status: active.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2005-001117-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001117-17.